Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.55 |
| ▸ | ACE | P12821 | 8/20 | 0.55 |
| ▸ | CPA1 | P15085 | 4/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21261666 | 0.90 | MME (0.58) | MMEACECPA1ACE2MMP3 | |
| SCHEMBL21244270 | 0.90 | MME (0.58) | MMEACECPA1ACE2MMP3 | |
| SCHEMBL21244271 | 0.90 | MME (0.58) | MMEACECPA1ACE2MMP3 | |
| SCHEMBL21610015 | 0.81 | PSMB5 (0.69) | — | |
| SCHEMBL17948648 | 0.80 | CPA1 (0.63) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL10087282 | 0.79 | MME (0.60) | MMEACECPA1ACE2MMP3 | |
| SCHEMBL7031374 | 0.79 | ACE (0.73) | MMEACECPA1ACE2 | |
| SCHEMBL20284366 | 0.79 | CTSL (0.52) | MMEACECPA1ACE2MMP1 | |
| SCHEMBL11119114 | 0.78 | MME (0.69) | MMEACECPA1ACE2 | |
| SCHEMBL11119113 | 0.78 | MME (0.69) | MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519197-B1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519197-B1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | MME 567/4885ACE 983/4885CPA1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.